Hengrui PD-L1 monoantigen initiated Phase III clinical target for small cell lung cancer

Text . . Plus January 5, Insight database shows that Hengrui PD-L1 single anti-SHR-1316 launched a Phase III clinical, combined radiotherapy bureau limited to small cell lung cancer.
SHR-1316 from insight database () is a PD-L1 product developed by Hengrui, which relieves the immunosuppressive effect of PD-L1 mediated, enhances the function of lethal T cells, and plays a role in mobilizing the body's immune system to remove tumor cells in the body.
first submitted a clinical trial application in February 2017 and was approved for clinical trial in September of the same year.
currently, SHR-1316 has initiated 6 clinical trials, including 3 Phase III clinical trials, for non-small cell lung cancer perioperative, broad-stage small cell lung cancer, and indocular small cell lung cancer.
The clinical trial initiated by insight database () is a randomized, double-blind, controlled, multi-center Phase III clinical study designed to evaluate the safety and effectiveness of SHR-1316/placebo combined platinum chemotherapy (etoposide plus carpiate) for the treatment of small cell lung cancer.
trials will be conducted at 39 hospitals across the country, with a planned group of 498 people.
the main endpoint index is the occurrence and total survival of adverse events assessed by CTCAE v5.0, and the secondary endpoint index is no progress survival, objective mitigation rate, mitigation duration, etc.
the clinical trials that have been initiated, SHR-1316 adaptations for the treatment of esophageal cancer have also been approved for clinical use.
from the Insight database () the current PD-L1 single resistance, the imported products Durvalumab and Atezolizumab have been approved for listing in China.
public data, total global sales of PD-L1 single resistance in 2019 will be approximately $3.508 billion.
And domestic same-target products have not yet been approved, in the research products to the cornerstone of the pharmaceutical industry CS1001 and Corning Jerry / Idea Dee / Synonym cooperation of the Nwolly monoanti (KN035) has been the fastest progress, has been reported for the market.
addition, 3 other projects are in Phase III clinical, 5 projects are in Phase II clinical, and 5 projects are in Phase I clinical.
from insight database ()